The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
September 30, 2024
Imetelstat (Rytelo) for Myelodysplastic Syndromes (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Imetelstat (Rytelo) for Myelodysplastic Syndromes (online only)
September 30, 2024 (Issue: 1712)
The FDA has approved imetelstat (Rytelo – Geron),
a first-in-class telomerase inhibitor, for treatment
of low- to intermediate-1 risk myelodysplastic
syndromes (MDS) in adults with transfusion-dependent
anemia requiring 4 or more red blood...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.